CL2013002551A1 - Molecula de anticuerpo contra dabigatran; metodo de fabricacion; y su uso para tratar o prevenir los efectos secundarios de la terapia con anticoagulantes o de un evento de sobredosis en la terapia con anticoagulantes. - Google Patents

Molecula de anticuerpo contra dabigatran; metodo de fabricacion; y su uso para tratar o prevenir los efectos secundarios de la terapia con anticoagulantes o de un evento de sobredosis en la terapia con anticoagulantes.

Info

Publication number
CL2013002551A1
CL2013002551A1 CL2013002551A CL2013002551A CL2013002551A1 CL 2013002551 A1 CL2013002551 A1 CL 2013002551A1 CL 2013002551 A CL2013002551 A CL 2013002551A CL 2013002551 A CL2013002551 A CL 2013002551A CL 2013002551 A1 CL2013002551 A1 CL 2013002551A1
Authority
CL
Chile
Prior art keywords
anticoagulant therapy
treat
manufacturing
prevent
side effects
Prior art date
Application number
CL2013002551A
Other languages
English (en)
Spanish (es)
Inventor
Ryn Joanne Van
Tobias Litzenburger
Keith Canada
Robert Copenhaver
Norbert Hauel
Sanjaya Singh
Alisa K Waterman
Christopher Ronald Sarko
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002551(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2013002551A1 publication Critical patent/CL2013002551A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2013002551A 2011-03-30 2013-09-05 Molecula de anticuerpo contra dabigatran; metodo de fabricacion; y su uso para tratar o prevenir los efectos secundarios de la terapia con anticoagulantes o de un evento de sobredosis en la terapia con anticoagulantes. CL2013002551A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161469207P 2011-03-30 2011-03-30

Publications (1)

Publication Number Publication Date
CL2013002551A1 true CL2013002551A1 (es) 2014-02-14

Family

ID=45876804

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002551A CL2013002551A1 (es) 2011-03-30 2013-09-05 Molecula de anticuerpo contra dabigatran; metodo de fabricacion; y su uso para tratar o prevenir los efectos secundarios de la terapia con anticoagulantes o de un evento de sobredosis en la terapia con anticoagulantes.

Country Status (23)

Country Link
US (2) US8821871B2 (OSRAM)
EP (1) EP2691156A1 (OSRAM)
JP (1) JP2014515740A (OSRAM)
KR (1) KR20140009437A (OSRAM)
CN (1) CN103476459A (OSRAM)
AP (1) AP2013007046A0 (OSRAM)
AR (1) AR085758A1 (OSRAM)
BR (1) BR112013025031A2 (OSRAM)
CA (1) CA2827787A1 (OSRAM)
CL (1) CL2013002551A1 (OSRAM)
CO (1) CO6771448A2 (OSRAM)
EA (1) EA201301090A1 (OSRAM)
EC (1) ECSP13012997A (OSRAM)
IL (1) IL227653A0 (OSRAM)
MA (1) MA34978B1 (OSRAM)
MX (1) MX2013011092A (OSRAM)
PE (1) PE20140964A1 (OSRAM)
PH (1) PH12013501924A1 (OSRAM)
SG (1) SG193552A1 (OSRAM)
TN (1) TN2013000388A1 (OSRAM)
TW (1) TW201302796A (OSRAM)
UY (1) UY33994A (OSRAM)
WO (1) WO2012130834A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012097313A2 (en) 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
KR101892330B1 (ko) 2011-11-29 2018-08-27 페로스피어 파마슈티컬스 인코포레이티드 항응혈 역전 물질들
EP3003390B1 (en) * 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
AU2014298540B2 (en) * 2013-07-30 2018-08-09 Janssen Sciences Ireland Uc Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections
KR101523503B1 (ko) * 2013-09-17 2015-05-29 강원대학교산학협력단 아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
JP2016539926A (ja) 2013-10-25 2016-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗凝血薬の解毒剤
EP2980218A1 (en) * 2014-07-30 2016-02-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamer thrombin complex for use as an antidote to direct acting thrombin inhibitors
WO2019210270A2 (en) * 2018-04-27 2019-10-31 Seattle Children's Hospital D/B/A Seattle Children's Research Institute In vivo gene therapy using delivery of a lentiviral gene construct

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU676150B2 (en) 1992-01-23 1997-03-06 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
DE4203965A1 (de) 1992-02-11 1993-08-12 Max Planck Gesellschaft Antidot fuer hirudin und synthetische thrombininhibitoren
ATE452975T1 (de) 1992-08-21 2010-01-15 Univ Bruxelles Immunoglobuline ohne leichte ketten
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
ATE157100T1 (de) 1993-06-03 1997-09-15 Therapeutic Antibodies Inc Antikoerperfragmente in therapie
AT404357B (de) 1995-06-13 1998-11-25 Immuno Ag Prothrombin-derivate
DE19605126A1 (de) 1996-02-12 1997-08-14 Basf Ag Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en) 1996-06-11 2001-03-13 Commonwealth Biotechnologies, Inc. Heparin binding peptides
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
PE121699A1 (es) 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
JP2002505574A (ja) 1997-04-30 2002-02-19 エンゾン，インコーポレイテッド ポリアルキレンオキシド修飾された単鎖ポリペプチド
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en) 1999-03-17 2003-09-23 The Regents Of The University Of Michigan Protamine fragment compositions and methods of use
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
MXPA03006358A (es) 2001-01-17 2004-12-02 Trubion Pharmaceuticals Inc Proteinas de fusion dominio de enlace-inmunoglobulina.
US20040097547A1 (en) 2001-04-16 2004-05-20 Taveras Arthur G. 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
EP1456410A2 (en) 2001-12-11 2004-09-15 AlgoNomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
EP2135879A3 (en) 2002-06-28 2010-06-23 Domantis Limited Ligand
NZ540196A (en) 2002-11-08 2008-09-26 Ablynx Nv Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders
DK1639011T3 (da) 2003-06-30 2009-02-16 Domantis Ltd Pegylerede enkelt-domæne antistoffer (dAb)
KR102069498B1 (ko) 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Ｘａ 저해제에 대한 안티도트 및 그것을 사용하는 방법
CA2767966A1 (en) 2009-08-24 2011-03-03 Boehringer Ingelheim International Gmbh Emergency interventions of active charcoal with dabigatran etexilate overdosing
AR079944A1 (es) 2010-01-20 2012-02-29 Boehringer Ingelheim Int Anticuerpo neutralizante de la actividad de un anticoagulante

Also Published As

Publication number Publication date
UY33994A (es) 2012-09-28
WO2012130834A1 (en) 2012-10-04
TW201302796A (zh) 2013-01-16
BR112013025031A2 (pt) 2017-08-01
US20120276123A1 (en) 2012-11-01
CO6771448A2 (es) 2013-10-15
TN2013000388A1 (en) 2015-01-20
IL227653A0 (en) 2013-09-30
JP2014515740A (ja) 2014-07-03
AP2013007046A0 (en) 2013-08-31
CN103476459A (zh) 2013-12-25
CA2827787A1 (en) 2012-10-04
US8821871B2 (en) 2014-09-02
MA34978B1 (fr) 2014-03-01
PE20140964A1 (es) 2014-08-17
PH12013501924A1 (en) 2017-10-25
ECSP13012997A (es) 2013-12-31
NZ613543A (en) 2015-07-31
EP2691156A1 (en) 2014-02-05
EA201301090A1 (ru) 2014-05-30
AR085758A1 (es) 2013-10-23
US20140377265A1 (en) 2014-12-25
KR20140009437A (ko) 2014-01-22
SG193552A1 (en) 2013-11-29
MX2013011092A (es) 2013-12-06

Similar Documents

Publication Publication Date Title
CL2013002551A1 (es) Molecula de anticuerpo contra dabigatran; metodo de fabricacion; y su uso para tratar o prevenir los efectos secundarios de la terapia con anticoagulantes o de un evento de sobredosis en la terapia con anticoagulantes.
IL263175B (en) Microbiota restoration therapy (mrt), compositions and methods of manufacture
IL239922A0 (en) Solid solution compositions and use in chronic inflammation
DK3329909T3 (da) Fenfluramin til anvendelse i behandling af dravet syndrom
BR112013031647A2 (pt) polissacarídeo péctico e método para produzir o mesmo
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
BR112014018136A2 (pt) anticorpos ou uso e método para determinar
DK2761126T3 (da) Wellbore stimulation assemblies and methods of using the same
IL239920A0 (en) Compositions and methods for treating chronic inflammation and inflammatory diseases
IL269166A (en) Methods and compositions for treating inflammation
SMT201600144B (it) Nuovi derivati eterociclici e loro uso nel trattamento di disturbi neurologici
BR112014010162A8 (pt) uso de composição, método para melhorar o reconhecimento e/ou tratar ou prevenir função de reconhecimento prejudicada em um indivíduo, e composição
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
MX2015014512A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
BR112014009634A2 (pt) preparação e agente terapêutico
MX367241B (es) Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer.
BR112015023203A8 (pt) métodos para tratamento de câncer, método para aumentar a eficiência de um tratamento de câncer, método para retardar e/ou prevenir o desenvolvimento de câncer, método para tratar um indivíduo com câncer, método para aumentar a sensibilidade para um agente de terapia para câncer, método para estender um período de sensibilidade e método para estender a duração da resposta para uma terapia para câncer.
IL228771A0 (en) Glycoside derivatives and their uses for the treatment of diabetes
BR112015002706A2 (pt) niclosamida e seus derivados para uso no tratamento de tumores sólidos
UA117466C2 (uk) СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica
CL2013002006A1 (es) Composicion farmaceutica que comprende un anticuerpo aislado que se une especificamente al factor de celulas madres; metodo de produccion del anticuerpo; y su uso para tratar o prevenir una enfermedad de remodelacion tisular o fibrotica en un sujeto.
BR112014031512A2 (pt) composição cosmética e método para o tratamento cosmético.
SMT201600154B (it) DERIVATI DI ORVlNOLO E DI TEVINOLO UTILI NEL TRATTAMENTO DI UN ABUSO DI DROGA E DI ALCOOL
CO6870047A2 (es) Soporte basado en fibras celulósicas y/o sintéticas, método para producirlo y uso del soporte